Ginkgo BioWorks And XWELL Are Expanding Their Work With The U.S. Centers For Disease Control And Prevention's Traveler-based Genomic Surveillance Program To Test For More Than 30 Additional Priority Pathogens, In Addition To SARS-COV-2
Portfolio Pulse from Benzinga Newsdesk
Ginkgo BioWorks and XWELL are expanding their collaboration with the U.S. Centers for Disease Control and Prevention's traveler-based genomic surveillance program. They will now test for more than 30 additional priority pathogens, besides SARS-COV-2.
November 06, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The expansion of Ginkgo BioWorks and XWELL's work with the CDC could potentially increase the demand for DNA testing services.
The news of Ginkgo BioWorks and XWELL expanding their work with the CDC to test for more pathogens could potentially increase the demand for DNA testing services. This could have a positive impact on the stock price of DNA in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50